The maker of an unproven drug intended to prevent premature births says it will voluntarily remove the product from the United States
, though Covis has repeatedly appealed for more time to conduct additional research. The injectable drug has become a symbol for the challenges the FDA faces to withdraw a medication when the manufacturer won't do so voluntarily.
The company said that extended off-ramp would give women who are still receiving the drug time to finish their course of treatment, which involves weekly injections starting after 16 weeks of pregnancy. Covis said it made its proposal to the FDA following an October public meeting at which outside advisers overwhelmingly concluded that Makena hasn’t been shown to work and should have its approval revoked. Despite hours of presentations and debate, the panel was unconvinced by arguments from Covis that the drug could be useful for a subgroup of women.
“While we stand by Makena’s favorable benefit-risk profile, including its efficacy in women at highest risk of preterm birth, we are seeking to voluntarily withdraw the product and work with the FDA to effectuate an orderly wind-down,” said Raghav Chari, Covis' chief information officer, in a statement.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Maker of preterm birth drug Makena to withdraw it from market | CNNThe maker of the drug Makena, which was approved more than a decade ago to reduce the risk of preterm birth, said Tuesday that it is moving to withdraw the medication from the market after a US Food and Administration panel said it is not effective.
Weiterlesen »
Drug to Prevent Preterm Births to Be Pulled From MarketThe maker of Makena said it will stop selling the drug to prevent preterm births after a study couldn’t confirm the medicine worked
Weiterlesen »
Chinese EV maker announces satellite constellation to support new carsGeely is promising centimeter-level positioning accuracy with its own satellite constellation to be launched by 2025. This is expected to support driving features.
Weiterlesen »
Marlboro maker Altria agrees to buy e-cigarette startup NJOY for nearly $2.8 billionAltria's deal to buy NJOY comes after the Marlboro maker exited its position in Juul Labs.
Weiterlesen »
Altria buying vape maker NJOY for $2.75BAltria will buy vape-maker NJOY and absorb the company’s NJOY ACE production as the only e-vapor product with market authorizations from the U.S. Food and Drug Administration (FDA).
Weiterlesen »